Trial Profile
A single center study to evaluate the long term outcomes with alemtuzumab induction therapy in renal transplant recipients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Aug 2015
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Methylprednisolone; Mycophenolate mofetil; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 20 Aug 2015 New trial record